Gender differences in renal nuclear receptors and aryl hydrocarbon receptor in 5/6 nephrectomized rats

Kidney International

Volumn 70, Issue 11, 2006, Pages 1920-1928

  Lu, H ^a   Lei, X ^a   Klaassen, C ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; Gender; Nuclear receptor; Steroid hormone

Indexed keywords

ACYL COENZYME A OXIDASE; ANDROGEN RECEPTOR; AROMATIC HYDROCARBON RECEPTOR; CELL NUCLEUS RECEPTOR; CORTICOSTERONE; CYTOCHROME P450 4A1; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TESTOSTERONE; TRANSCRIPTION FACTOR; WT1 PROTEIN;

ALBUMINURIA; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; ESTRADIOL BLOOD LEVEL; FEMALE; GENE AMPLIFICATION; INFLAMMATORY DISEASE; INJURY SEVERITY; KIDNEY INJURY; KIDNEY TRANSPLANTATION; MALE; MALNUTRITION; NEPHRECTOMY; NEPHRITIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SEX DIFFERENCE; SURGICAL INJURY; SYSTEMIC DISEASE; TESTOSTERONE BLOOD LEVEL;

ACYL-COA OXIDASE; ALKANE 1-MONOOXYGENASE; ANIMALS; CASPASE 3; CORTICOSTERONE; DISEASE PROGRESSION; ESTRADIOL; FEMALE; GENE EXPRESSION; KIDNEY; MALE; NEPHRECTOMY; PPAR ALPHA; RATS; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, STEROID; RENAL INSUFFICIENCY, CHRONIC; RNA, MESSENGER; SEX CHARACTERISTICS; TESTOSTERONE; WT1 PROTEINS;

EID: 33845267001     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001880     Document Type: Article

References (62)

1. Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl 2005; 6: S7-S10.
2. Okamoto T. Requirement of drug development for chronic renal disease: other strategies than blockade of the renin-angiotensin system. Int J Mol Med 2003; 11: 651-654.
3. Silbiger SR, Neugarten J. The role of gender in the progression of renal disease. Adv Renal Replace Ther 2003; 10: 3-14.
4. Coggins CH, Breyer Lewis J, Caggiula AW et al. Differences between women and men with chronic renal disease. Nephrol Dial Transplant 1998; 13: 1430-1437.
5. Ishikawa I, Saito Y, Nakamura M et al. Fifteen-year follow-up of acquired renal cystic disease - a gender difference. Nephron 1997; 75: 315-320.
6. Lemos CC, Mandarim-de-Lacerda CA, Dorigo D et al. Chronic renal failure in male and female rats. J Nephrol 2005; 18: 368-373.
7. Schwartzman ML, da Silva JL, Lin F et al. Cytochrome P450 4A expression and arachidonic acid omega-hydroxylation in the kidney of the spontaneously hypertensive rat. Nephron 1996; 73: 652-663.
8. Ishizuka T, Ito O, Tan L et al. Regulation of cytochrome P-450 4A activity by peroxisome proliferator-activated receptors in the rat kidney. Hypertens Res 2003; 26: 929-936.
9. Portilla D. Energy metabolism and cytotoxicity. Semin Nephrol 2003; 23: 432-438.
10. Guan Y. Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease. Minerva Urol Nefrol 2002; 54: 65-79.
11. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001; 169: 453-459.
12. Bocher V, Chinetti G, Fruchart JC, Staels B. Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control. J Soc Biol 2002; 196: 47-52.
13. Portilla D, Dai G, Peters JM et al. Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. Am J Physiol Renal Physiol 2000; 278: F667-F675.
14. Li S, Gokden N, Okusa MD et al. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 2005; 289: F469-F480.
15. Falahatpisheh MH, Ramos KS. Ligand-activated Ahr signaling leads to disruption of nephrogenesis and altered Wilms' tumor suppressor mRNA splicing. Oncogene 2003; 22: 2160-2171.
16. Mimura J, Yamashita K, Nakamura K et al. Loss of teratogenic response to 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking the Ah (dioxin) receptor. Genes Cells 1997; 2: 645-654.
17. Chang CY, Puga A. Constitutive activation of the aromatic hydrocarbon receptor. Mol Cell Biol 1998; 18: 525-535.
18. Safe S, Wormke M. Inhibitory aryl hydrocarbon receptor-estrogen receptor alpha cross-talk and mechanisms of action. Chem Res Toxicol 2003; 16: 807-816.
19. Carlson DB, Perdew GH. A dynamic role for the Ah receptor in cell signaling? Insights from a diverse group of Ah receptor interacting proteins. J Biochem Mol Toxicol 2002; 16: 317-325.
20. Wormke M, Stoner M, Saville B et al. The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes. Mol Cell Biol 2003; 23: 1843-1855.
21. Dalton TP, Puga A, Shertzer HG. Induction of cellular oxidative stress by aryl hydrocarbon receptor activation. Chem Biol Interact 2002; 141: 77-95.
22. Senft AP, Dalton TP, Nebert DW et al. Mitochondrial reactive oxygen production is dependent on the aromatic hydrocarbon receptor. Free Radical Biol Med 2002; 33: 1268-1278.
23. Sindhu RK, Vaziri ND. Upregulation of cytochrome P450 1A2 in chronic renal failure: does oxidized tryptophan play a role? Adv Exp Med Biol 2003; 527: 401-407.
24. Kang DH, Yu ES, Yoon KI, Johnson R. The impact of gender on progression of renal disease: potential role of estrogen-mediated vascular endothelial growth factor regulation and vascular protection. Am J Pathol 2004; 164: 679-688.
25. Silbiger SR, Neugarten J. The impact of gender on the progression of chronic renal disease. Am J Kidney Dis 1995; 25: 515-533.
26. Muller V, Szabo A, Viklicky O et al. Sex hormones and gender-related differences: their influence on chronic renal allograft rejection. Kidney Int 1999; 55: 2011-2020.
27. Antus B, Yao Y, Song E et al. Opposite effects of testosterone and estrogens on chronic allograft nephropathy. Transpl Int 2002; 15: 494-501.
28. Ohtsuka N, Sakemi T, Tomiyoshi Y, Morito F. Different effect of estrogen administration from castration on glomerular injury in unilaterally nephrectomized male Sprague-Dawley rats. Nephron 1997; 77: 445-451.
29. Cayzergues L, Yaici el D, Tabard SB et al. Morphological study of the spinal motoneurons controlling the urethral sphincter of female rats: role of androgens in a menopausal model. J Urol 2005; 173: 1022-1026.
30. Quinkler M, Bumke-Vogt C, Meyer B et al. The human kidney is a progesterone-metabolizing and androgen-producing organ. J Clin Endocrinol Metab 2003; 88: 2803-2809.
31. Jelinsky SA, Harris HA, Brown EL et al. Global transcription profiling of estrogen activity: estrogen receptor alpha regulates gene expression in the kidney. Endocrinology 2003; 144: 701-710.
32. Potier M, Karl M, Zheng F et al. Estrogen-related abnormalities in glomerulosclerosis-prone mice: reduced mesangial cell estrogen receptor expression and prosclerotic response to estrogens. Am J Pathol 2002; 160: 1877-1885.
33. Baltatu O, Cayla C, Iliescu R et al. Abolition of end-organ damage by antiandrogen treatment in female hypertensive transgenic rats. Hypertension 2003; 41: 830-833.
34. Newton CJ, Ran G, Xie YX et al. Statin-induced apoptosis of vascular endothelial cells is blocked by dexamethasone. J Endocrinol 2002; 174: 7-16.
35. Moran TJ, Gray S, Mikosz CA, Conzen SD. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res 2000; 60: 867-872.
36. Muller DN, Shagdarsuren E, Park JK et al. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 2002; 161: 1679-1693.
37. Kostadinova R, Wahli W, Michalik L. PPARs in diseases: control mechanisms of inflammation. Curr Med Chem 2005; 12: 2995-3009.
38. Vanden Berghe W, Vermeulen L, Delerive P et al. A paradigm for gene regulation: inflammation NF-kappaB and PPAR. Adv Exp Med Biol 2003; 544: 181-196.
39. Hashimoto T, Fujita T, Usuda N et al. Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J Biol Chem 1999; 274: 19228-19236.
40. Holla VR, Adas F, Imig JD et al. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci USA 2001; 98: 5211-5216.
41. Cummings BS, Lasker JM, Lash LH. Expression of glutathione-dependent enzymes and cytochrome P450s in freshly isolated and primary cultures of proximal tubular cells from human kidney. J Pharmacol Exp Ther 2000; 293: 677-685.
42. Gainer JV, Bellamine A, Dawson EP et al. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 2005; 111: 63-69.
43. Hoch U, Zhang Z, Kroetz DL, Ortiz de Montellano PR. Structural determination of the substrate specificities and regioselectivities of the rat and human fatty acid omega-hydroxylases. Arch Biochem Biophys 2000; 373: 63-71.
44. Cowart LA, Wei S, Hsu MH et al. The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator- activated receptor ligands. J Biol Chem 2002; 277: 35105-35112.
45. Fleming I. Cytochrome P-450 under pressure: more evidence for a link between 20-hydroxyeicosatetraenoic acid and hypertension. Circulation 2005; 111: 5-7.
46. Moreno C, Maier KG, Hoagland KM et al. Abnormal pressure-natriuresis in hypertension: role of cytochrome P450 metabolites of arachidonic acid. Am J Hypertens 2001; 14: 90S-97S.
47. Sarkis A, Roman RJ. Role of cytochrome P450 metabolites of arachidonic acid in hypertension. Curr Drug Metab 2004; 5: 245-256.
48. Ito O, Alonso-Galicia M, Hopp KA, Roman RJ. Localization of cytochrome P-450 4A isoforms along the rat nephron. Am J Physiol 1998; 274: F395-F404.
49. Kimura S, Hardwick JP, Kozak CA, Gonzalez FJ. The rat clofibrate-inducible CYP4A subfamily. II. cDNA sequence of IVA3, mapping of the Cyp4a locus to mouse chromosome 4, and coordinate and tissue-specific regulation of the CYP4A genes. DNA 1989; 8: 517-525.
50. Iturralde M, Gamen S, Pardo J et al. Saturated free fatty acid release and intracellular ceramide generation during apoptosis induction are closely related processes. Biochim Biophys Acta 2003; 1634: 40-51.
51. Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 2000; 275: 36703-36707.
52. Muller DN, Theuer J, Shagdarsuren E et al. A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. Am J Pathol 2004; 164: 521-532.
53. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 1988; 62: 367-374.
54. Nakagawa K, Marji JS, Schwartzman ML et al. Androgen-mediated induction of the kidney arachidonate hydroxylases is associated with the development of hypertension. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1055-R1062.
55. Guo JK, Menke AL, Gubler MC et al. WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Hum Mol Genet 2002; 11: 651-659.
56. Rivera MN, Haber DA. Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer 2005; 5: 699-712.
57. Hammes A, Guo JK, Lutsch G et al. Two splice variants of the Wilms' tumor 1 gene have distinct functions during sex determination and nephron formation. Cell 2001; 106: 319-329.
58. Nihei T, Miura Y, Yagasaki K. Inhibitory effect of resveratrol on proteinuria, hypoalbuminemia and hyperlipidemia in nephritic rats. Life Sci 2001; 68: 2845-2852.
59. Leazer TM, Klaassen CD. The presence of xenobiotic transporters in rat placenta. Drug Metab Dispos 2003; 31: 153-167.
60. Hartley DP, Klaassen CD. Detection of chemical-induced differential expression of rat hepatic cytochrome P450 mRNA transcripts using branched DNA signal amplification technology. Drug Metab Dispos 2000; 28: 608-616.
61. Harstad EB, Klaassen CD. Analysis of strain difference in sensitivity to cadmium-induced hepatotoxicity in Fischer 344 and Sprague-Dawley rats. Toxicol Sci 2002; 67: 329-340.
62. Slitt AL, Cherrington NJ, Maher JM, Klaassen CD. Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites. Drug Metab Dispos 2003; 31: 1176-1186.